



 **37**
Physicians & 23 Advance practice providers

 **4**
Locations

 **8,000**
New patients annually

 **43**
Phase I, II, & III studies annually

 **60+**
Helped develop more than 60 FDA approved cancer therapies

About Compass Oncology

Compass Oncology is the Portland metropolitan area's trusted resource for cancer care and diseases of the blood. We provide comprehensive, leading-edge treatment incorporating the tools of evidence-based medicine, clinical trials and research studies.

Everyday our team of nearly 400 dedicated and compassionate professionals come to work committed to Compass' mission: *Together, we navigate your care close to home, every step of the way.*

Modern cancer treatment frequently includes a combination of therapies from different specialties. The Compass Oncology team brings together leading experts in the fields of surgical, medical and radiation oncology, and palliative care to provide the most comprehensive cancer care possible and a more cohesive patient experience. Our community-based sites allow for the delivery of quality care at reduced cost relative to hospital-based oncology centers.

Compass oncologists are at the forefront of discovery. As a member of The US Oncology Network, one of the nation's largest community-based cancer treatment and research networks, Compass Oncology participates in leading-edge clinical trials through US Oncology research, which has helped develop more than 60 FDA approved cancer therapies. With 4 locations in the Portland/Vancouver metropolitan area our network of more than 37 physicians and 23 Advanced Practice Providers is collectively focused on treating cancer and blood disorders with leading-edge technology and innovative research no matter where patients live.

About Willamette Valley Cancer Institute and Research Center

Founded in 1997, Willamette Valley Cancer Institute (WVCI) is an independent, physician-led practice that began in Eugene, Oregon. Its founders pioneered community-based oncology care in the southern Willamette Valley by bringing together experts in medical oncology, hematology, radiation oncology, and gynecologic oncology under one roof. Their partnership and commitment to excellence has enabled more patients to receive high-quality cancer care while staying close to home, near the critical support of family and friends. The practice has grown with the community, expanded to help other small communities in the valley by establishing community-based clinics in Albany, Corvallis, Florence, Lincoln City, Newport, and Springfield.

As a leader in innovative healthcare programs, Willamette Valley Cancer Institute has participated in value-based healthcare models to reduce the cost of care and improve population health. WVCI actively participates in national and state debates over cost of care, the cost of drugs, biosimilars, and the importance of community oncology in patient access to care and treatment.

Compass and WVCI are part of The US Oncology Network, one of the nation's largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. The Network unites like-minded physicians and clinicians around a common vision of expanding patient access to the highest quality state-of-the-art care close to home, and at lower costs for patients and the health care system. The Network treats approximately 850,000 cancer patients annually in more than 400 locations across 27 states.

 **33**
Physicians & 9 Advance practice providers

 **7**
Locations

 **4,000**
New patients annually

 **40**
Phase I, II, & III studies annually

 **75+**
Helped develop more than 75 FDA approved cancer therapies

Support Reasonable Tax Relief that Benefits Oregon Cancer Patients and Independent Oncologists **Compass Oncology and Willamette Valley Cancer Institute Support SB 56, Findley**

In 2019, the Oregon legislature imposed a Corporate Activity Tax on businesses' commercial activity. Though the bill excludes hospitals and long-term care facilities, it broadly applies to medical entities – including independent community oncology practices. While other businesses pass this tax to consumers, community oncologists will not pass this cost onto patients. Consequently, independent providers must pay the CAT and absorb the cost of taxes applied at each step in the supply chain, including the procurement of critical cancer drugs. Unlike businesses, oncologists don't set prices within a free market. Instead, we receive modest reimbursement from government payers, which often pay less than the actual costs of care which make up a large portion of our patients. To ensure community oncology's long-term viability and protect cancer patients, we urge the Oregon Legislature to support SB 56 and policies like it, that provide significant relief to our state's independent oncology providers.

SB 56 exempts from taxable commercial activity reimbursements for certain health care services, including care provided to medical assistance recipients and to Medicare recipients and receipts from medications administered or dispensed in a clinical setting other than hospital.

Preserve and Protect Patient Choice and Access to Safe and Timely Care **Compass Oncology and Willamette Valley Cancer Institute Support HB 2715, Scharf**

Insurers and Pharmacy Benefit Managers (PBMs) are mandating policies that steer patients to receive physician-administered drugs, like chemotherapy, from PBM-affiliated or PBM-owned specialty pharmacies. Chemotherapies consist of complex drug regimens that are dynamic, patient-specific, frequently adjusted at the point of care and prepared on site based on a patient's ever-changing circumstance (such as disease progression, co-morbidities, and weight variation, as well as the drug's toxicities and side effects). These insurer mandated policies steer patients and require physician-administered drugs to be pre-ordered days in advance and shipped to the physician's office for administration. Pre-ordered drugs based on a patients' prior circumstance do not allow for crucial same day dose adjustments. This practice delays patients' access to timely care which leads to disease progression and interferes with the normal course of treatment on how cancer care is delivered today.

HB 2715 prohibits health insurers and pharmacy benefit managers from restricting coverage of physician administered prescription drugs that are obtained by nonparticipating pharmacies. HB 2715 would prohibit PBMs from requiring a physician administered drug be obtained by their specialty pharmacy. This is a practice known as white bagging and it is proven to be unsafe for cancer treatment, increases drug waste, raises treatment cost and should not be mandated by insurance companies in Oregon.

Support Reimbursement for Health Care Interpreters **Compass Oncology and Willamette Valley Cancer Institute Support HB 2538, Reynolds**

HB 2538 would ensure clinician reimbursement for health care interpretation services. In 2021 HB 2359 was signed into law and requires clinicians to provide certified health care interpretation services to patients. Currently, independent physicians are responsible for covering the full cost of services for patients who have commercial insurance, or those uninsured. In 2022, health care interpretation services cost Compass Oncology and Willamette Valley Cancer Institute a significant amount of money out of pocket. Many of our patients that require these important services come from vulnerable populations with insurance that have low reimbursement rates. That said, we pride ourselves treating those who other providers may turn away based on their insurance type or for being uninsured. We believe these services are vital to our patients, but the cost should not be solely placed on the independent provider. We ask for your support of HB 2538.